Alpha 2.0
Login Register
» Articles » PMID: 24727998

Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Overview
Journal Blood Cancer J
Date 2014 Apr 15
PMID 24727998
Citations 5
Authors
D S Siegel
P Richardson
M Dimopoulos
P Moreau
C Mitsiades
D Weber
J Houp
C Gause
S Vuocolo
J Eid
T Graef
K C Anderson
Affiliations
Soon will be listed here.
Citing Articles

Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Jan M, Sperling A, Ebert B Nat Rev Clin Oncol. 2021; 18(7):401-417.

PMID: 33654306 PMC: 8903027. DOI: 10.1038/s41571-021-00479-z.

Posttransplant maintenance therapy in multiple myeloma: the changing landscape.

Sengsayadeth S, Malard F, Savani B, Garderet L, Mohty M Blood Cancer J. 2017; 7(3):e545.

PMID: 28338672 PMC: 5380907. DOI: 10.1038/bcj.2017.23.

Novel agents in the treatment of multiple myeloma: a review about the future.

Naymagon L, Abdul-Hay M J Hematol Oncol. 2016; 9(1):52.

PMID: 27363832 PMC: 4929712. DOI: 10.1186/s13045-016-0282-1.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E Oncotarget. 2015; 6(5):3319-34.

PMID: 25669970 PMC: 4413656. DOI: 10.18632/oncotarget.3207.

Treatment-related symptom management in patients with multiple myeloma: a review.

Colson K Support Care Cancer. 2015; 23(5):1431-45.

PMID: 25646616 DOI: 10.1007/s00520-014-2552-1.